Secured 38 CE certifications and 93 international approvals, driving 22% sales growth in H1 2025
[by Kang, In Hyo] 바카라 사이트 추천디시 Panagene, a molecular diagnostics company, announced on October 17 that it has completed the registration of eight independently developed cancer diagnostic products with the Drug Regulatory Authority of Pakistan (DRAP).
The newly approved products are mutation testing kits targeting eight different genetic mutations: KRAS (lung and colorectal cancers), BRAF (colorectal, thyroid, and skin cancers), EGFR (lung cancer), IDH1 (brain tumors), IDH2 (brain tumors), NRAS (colorectal and skin cancers), PIK3CA (breast cancer), and TERT (papillary thyroid cancer). Developed using HLB Panagene's proprietary ‘PNAClamp’ platform, these kits are designed to rapidly and accurately detect critical genetic mutations essential for therapeutic decision-making in major cancers, offering high sensitivity and precision.
By completing product registration in Pakistan, HLB Panagene has now secured a total of 38 European CE certifications (11 IVDRs and 27 IVDDs) and 93 certifications from global health authorities for its independently developed diagnostic products. This achievement reinforces the company’s global export base for molecular diagnostic solutions in oncology and infectious diseases, contributing to tangible results. In the first half of this year, HLB Panagene reported a year-on-year sales increase of approximately 22%, driven primarily by increased overseas exports.
"Since joining the HLB Group, we have reinforced our product portfolio through acquisitions such as Biosquare and consistently expanded our global network, thereby laying a solid foundation for growth. These efforts have led to a marked increase in sales and operating profit, and we intend to sustain this growth momentum to achieve even greater results in the future," said Jang In-keun, CEO of HLB Panagene.
Conversely, data from the Korea Trade-Investment Promotion Agency (KOTRA) indicate that Pakistan's economy grew by 2.4% in 2024 and is expected to reach approximately 3.5% this year. Notably, the country’s pharmaceutical industry is experiencing rapid growth, generating USD 3.3 billion in sales last year alone, a 22% increase compared to the previous year, and is regarded as a promising emerging market with substantial growth potential.